MedTrace Logo

Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma

NCT03541148 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-05-30

No results posted yet for this study

Summary

Malignant melanoma, responsible for 75% of deaths from skin cancer. Current therapeutic options have poor response, many adverse events and high costs. For this reason, a study with nutritional supplement Oncoxin-Viusid was carried out. According to previous studies, it has an antitumor, immunomodulatory effect and to potentiate the antiproliferative effect of standard chemotherapeutic agents in different locations and stages of cancer.

Conditions

  • Cutaneous Melanoma, Stage II
  • Malignant Cutaneous Melanoma
  • Cutaneous Melanoma, Stage III

Interventions

DIETARY_SUPPLEMENT

Oncoxin-Viusid

Oncoxin-Viusid supplement before/during/after standard surgical and adjuvant treatment or chemotherapy.

Sponsors & Collaborators

  • Catalysis SL

    lead INDUSTRY

Principal Investigators

  • Olaine R. Gray Lovio, Dr. · Manuel Fajardo Clinical Surgical University Hospital

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-16
Primary Completion
2016-04-13
Completion
2018-04-13

Countries

  • Cuba

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03541148 on ClinicalTrials.gov